Phase II
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
It was a busy week for clinical trial announcements and news. Here’s a look.
The company’s head of drug development, Samit Hirawat, told analysts in a conference call last week that the decision was about working with the best drugs, particularly in a crowded field like BCMA.
In the waning weeks of the fourth quarter of the 2020 fiscal year, AstraZeneca terminated several clinical programs, including some oncology and heart-related studies, as well as one COVID-19 related trial.
Switzerland-based AC Immune SA announced positive interim results from its ongoing Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease.
ZYESAMI is intended to block the replication of SARS-CoV-2 in the ATII cell, as well as cytokine synthesis, thereby relieving respiratory distress. It is the only treatment in development that targets these ATII cells, and if approved, would be the first drug on the market for COVID-19 patients critically ill with respiratory failure.
Tryp and Dr. Miller have begun designing a Phase 2a open-label, exploratory clinical study utilizing TRP-8802 in patients suffering from rare and orphan over-eating disorders.
Veru announced positive results from its Phase II trial of its VERU-111 compared to placebo in hospitalized patients at high risk for Acute Respiratory Distress Syndrome (ARDS) from COVID-19.
While the space is just beginning to emerge, therapies for long-haul COVID-19 patients are still very much an unmet need.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
PRESS RELEASES